Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours Β· Estimated delivery Jul 28 - Aug 2
Summary: GHK-Cu (copper peptide) has shown promise for hair loss in preclinical studies, but no robust human clinical trials have confirmed its efficacy, and it is not recommended by NICE or NHS as an evidence-based treatment
Intervening in periodontitis and modulating microbiota to treat neuropsychiatric disorders represents a paradigm shift in medicinefrom controlling localized infections to addressing systemic diseases
Some users report positive results, particularly when combining PTD-DBM with valproic acid and microneedling
Chemical class: synthetic pentadecapeptide, 15 residues, molecular mass approximately 1419.5 Da Original source: derived from a fragment of a gastric protective protein in human gastric juice Clinical-trial designation: PL14736 (early Pliva inflammatory bowel disease work) Approval status: not approved as a pharmaceutical in any jurisdiction
US$ 22.26
US$ 23.39
US$ 22.20
US$ 22.08
US$ 21.94
US$ 25.87